Lupin Expands US Inhalation Business With Two Sunovion Brands
Indian Firm Pays $75m For US Rights To Respiratory Brands Brovana And Xopenex HFA
Lupin has acquired all US market rights to Sunovion’s Brovana and Xopenex HFA branded inhalation products for $75m, strengthening its presence in the US respiratory market.
You may also be interested in...
Lupin has revealed details of the German launch of its Luforbec (beclometasone/formoterol) branded generic rival to Foster through its local Hormosan subsidiary, as part of the Indian firm’s wider push in the respiratory category.
Lupin has gained a long-awaited FDA approval for its US generic version of Spiriva. The product is seen as a major element of Lupin’s respiratory franchise and a key contributor to the Indian firm’s fortunes this year.
Lupin has offered further specifics on expected FDA action for its proposed Spiriva generic, as the Indian firm reported a solid third financial quarter that saw an uptick in sales and profits, including turnover growth in the US.